Related Experiment Video
Updated: May 12, 2026
Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery
Published on: June 2, 2022
Apnea of prematurity: caffeine dose optimization
Suzanne J Francart1, Megan K Allen, Jennifer Stegall-Zanation
1Department of Pharmacy, The University of North Carolina Hospitals and Clinics, Chapel Hill, North Carolina.
Insights
Higher maintenance doses of caffeine citrate (greater than 7.9 mg/kg/day) in premature neonates are safe and reduce the need for clinical interventions. This finding supports optimized caffeine therapy for apnea of prematurity.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Pediatric Critical Care
Background:
- Apnea of prematurity is common in neonates born before 28 weeks gestational age.
- Caffeine citrate is a standard treatment for apnea of prematurity.
- Optimal dosing strategies require further investigation.
Purpose of the Study:
- To evaluate the correlation between caffeine citrate maintenance dose and response rates in preterm neonates.
- To identify clinical indicators of response and adverse events like tachycardia.
Main Methods:
- Retrospective analysis of 89 neonates (<28 weeks gestational age) treated with caffeine citrate.
- Data collected on birth weight, gestational age, and caffeine dose.
- Comparison of clinical interventions and tachycardia incidence based on dose.
Main Results:
- Neonates receiving >7.9 mg/kg/day of caffeine citrate had fewer clinical interventions (76.3%) compared to those receiving ≤7.9 mg/kg/day (94.1%).
- The incidence of tachycardia was low across all treatment groups.
- Caffeine levels ranged from 16.6 to 34.4 μg/mL.
Conclusions:
- Caffeine citrate doses exceeding 7.9 mg/kg/day are safe for neonates under 28 weeks gestational age.
- Higher doses are associated with a reduced need for clinical interventions, suggesting improved efficacy.
- Optimized caffeine dosing may enhance treatment outcomes for apnea of prematurity.
Objectives:
The primary objective was to evaluate the correlation between maintenance dose and response rates in neonates less than 28 weeks gestational age. Secondary objectives included clinical indicators of response (number of weight adjustments, dose increases, and mini-loads) and tachycardia associated with caffeine therapy.
Methods:
This study was a retrospective analysis of neonates admitted to the North Carolina Children's Hospital from August 2009 to August 2011. Patients included were less than 28 weeks postmenstrual age and were treated with caffeine for apnea of prematurity. Patients were excluded if they were older than 28 weeks postmenstrual age, receiving caffeine therapy for other indications, or experiencing apnea from other conditions, or if therapy was initiated more than 7 days after birth.
Results:
A total of 89 neonates with a mean birth weight of 0.844 kg (range: 0.391 to 1.306 kg) and median gestational age of 26 2/7 weeks (range: 23 to 27 6/7 weeks) were evaluated. The median initial maintenance dose of caffeine citrate was 7.9 mg/kg/day, and 94.1% of neonates receiving ≤7.9 mg/kg/day required a clinical intervention during therapy compared with 76.3% in those receiving >7.9 mg/kg/day. Absolute incidence of tachycardia was low, and caffeine levels collected ranged from 16.6 to 34.4 μg/mL.
Conclusions:
In neonates less than 28 weeks gestational age, doses of caffeine citrate greater than 7.9 mg/kg/day are safe and are associated with a decreased need for clinical interventions.
More Related Videos
Related Concept Videos
01:29Drug Dosing: Infants and Children
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:22Cardiopulmonary Resuscitation II: ACLS Airway Management